Buradasınız

Anasayfa » Content

RANİTİDİN BİZMUT SİTRAT VE KLARİTROMİSİNLİ İKİLİ KOMBİNASYONLA ALTERNATİF HELİKOBAKTER PYLORİ TEDAVİSİ

RANITIDINE-BISMUTH CITRATE AND CLARITROMYCIN DOUBLE THERAPY AS ALTERNATIVE STRATEGY FOR HELICOBACTER PYLORI TREATMENT

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: To evaluate the efficacy of a strategy combining ranitidine-bismuth citrate (RBS) and clarithromycin double therapy for Helicobacter pylori (Hp) eradication with dudenal ulcer and/or gastrit 44 patients. Materials and methods: Forty four consecutive Hp-positive patients, with duodenal ulcer and/or gastrit were treated with 400 mg ranitidine-bismuth citrate twice daily for 30 days, 500 mg clarithromycin twice daily for 14 days between April 1998-May 1999. The efficacy of the treatment was evaluated by histology a month after treatment. Results: Forty four patients were 15 male, 29 female (mean age 45.93±14.03, range 17-85). Epigastric pain (100%), pyrozis, abdominal distension were common symptomes. This symptomes had regressed after treatment. Cure rates were 12/13 (92.3%) duodenal ulcer and 37/44 Hp-positive patients (84.09%). Conclus›ons: RBS and clarithromycin combination achieve good eradication rates (84.09%). As the first-line therapy avoids the use of RBS and clarithromycin combination, it could be useful in areas where high resistance lead to poor results with triple therapy.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Endoskopik incelemesinde Helikobakter pylori (Hp) enfeksiyonunun efllik etti¤i duodenal ülser ve/veya gastrit tesbit edilen 44 hastada Ranitidin bizmut sitrat (RBS) ve Klaritromisin kombinasyonunun tedavide etkinli- ¤ini araflt›rmak. Gereç ve yöntem:Nisan 1998, May›s 1999 tarihleri aras›nda gastroskopilerinde Hp enfeksiyonunun efllik etti¤i duodenal ülser ve/veya gastrit tesbit edilen, çal›flmaya al›nmay› kabul eden, ard›fl›k 44 hasta prospektif olarak çal›flmaya al›nd›. Hastalara 30 gün süreyle RBS 400 mg 2x1, 14 gün süreyle klaritromisin 500 mg 2x1 verildi, tedavi bitiminden 1 ay sonra kontrol endoskopik incelemeleri yap›ld›. Bulgular: 44 hastan›n 15’i erkek, 29’u kad›n; yafl ortalamas› 45,93±14,03 da¤›l›m› 17-85 idi. En s›k gözlenen semptomlar epigastrik a¤r› (%100), pirozis ve fliflkinlik idi. Tedavi sonras› hastalar›n flikayetlerinde belirgin gerileme gözlendi. Onüç duodenal ülserli hastadan 12’si iyileflti (% 92,3) ve 44 hastadan 37’sinde (% 84,09) Hp eradikasyonu sa¤land›. Sonuç: RBS ve klaritromisin kombinasyonuyla %84,09 oran›nda Hp eradikasyonu sa¤lanm›fl olup bu kombinasyonun klasik üçlü eradikasyon tedavisine özellikle dirençli bölgelerde alternatif olabilece¤i düflünüldü.
FULL TEXT (PDF): 
PDF icon arastirmax-ranitidin-bizmut-sitrat-klaritromisinli-ikili-kombinasyonla-alternatif-helikobakter-pylori-tedavisi.pdf
  • 3
61-64
  • Turkish

REFERENCES

References: 

1. Chiba N, Rao B, Rademaker JW, Hunt RH. Meta analysis of antibiotic
terapy ineradicating HP. Am Gastroenterol 1992;
87:1716-1727.
2. Demiray M, Gülten M, Manavo¤lu O, Evrensel T, Ulukaya E,
Yerci O, Kanat O, Kurt E, Arslan M, Gönüllü G, Demiray H,
Gülten T, Memik F. Evaluation of the effects of Helicobacter
pylori eradication therapy on gastric antral epithelial hyperproliferation:
a prospective six-month follow-up study. Hepatogastroenterology
2004; 51:1531-1535.
3. Dooley CP. Backgraund and historical considerations of HP.
Clin N Am 1993; 22:1-19.
4. Dooley CP, Cohen H. The clinical significance of campliyobacter
Pylori. Ann Intern Med 1998; 108: 70-9.
5. Johnston D, Martin I. Surgical treatment of duodenal and gastric
ulcer. In: Haaubric W, Schaffner F. Eds. Bockus Gastroenterology.
Phildelphia, Pa: WB Saunders Company 1995; 790-804.
6. Kate V, Ananthakrishnan N, Badrinath S. Effect of Helicobacter
pylori eradication on the ulcer recurrence rate after simple closure
of perforated duodenal ulcer: retrospective and prospective
randomized controlled studies. Br J Surg 2001; 88: 1054-1058.
7. Marhall BJ. Virulance and pathogenezis of HP eradication. J
Gastroenterol Hepatol 1991; 6:121-124.
8. Nada R, Bhasin DK, Joshi K, Sharma BC, Ray P, Pathak CM,
Singh K. Effect of eradication of Helicobacter pylori on gastric
antrum histology. Trop Gastroenterol 2002; 23:20-24.
9. Ong SP, Duggan A. Eradication of Helicobacter pylori in clinical
situations. Clin Exp Med 2004; 4: 30-38.
10. Panteris V, Karamanolis DG. Different aspects in functional
dyspepsia. Hepatogastroenterology 2005; 52:1782-1791.
11. Sachs G, Weeks DL, Melchers K, Scott DR. The gastric biology
of Helicobacter pylori. Annu Rev Physiol 2003; 65: 349-369.
12. Salih BA, Abas›yan›k MF, Sar›baflak H, Huten O, Sander E. A
follow-up study on the effect of Helicobacter pylori eradication
on the severity of gastric histology. Dig Dis Sci 2005; 50:1517-
1522.
13. Strnad M, Presecki V, Babus V, Turek S, Dominis M, Kalenic S,
Hebrang A, Katicic M. Epidemiology of Helicobacter pylori infection.
Lijec Vjesn 2002; 1: 5-9.
14. Solcia E, Villani L, Fiocca R, Boldorini R, Trespi E, Perego M,
Alvisi C, Lazzaroni M, Bianchi Porro G. Effect of eradication of
HP on gastritis in duodenal ulcer patients. Scand J Gastroenterol
1994; 201: 28-34.
15. Tomita T, Fukuda Y, Tamura K, Tanaka J, Hida N, Kosaka T, Hori
K, Sakagami T, Satomi M, Shimoyama T. Successful eradication
of Helicobacter pylori prevents relapse of peptic ulcer disease.
Aliment Pharmacol Ther 2002; 2:204-209.
16. Thijs JC, Kleibeuker JH. The management of univestigated
dyspepsia in primary care. Minerva Gastroenterol Dietol 2005;
51: 213-224.
17. Suriani R, Venturini I, Actis GC, Rocca G, Rizzetto M, Cerutti
E, Mazzucco D, Cardesi E, Zeneroli ML. Effect of Helicobacter
pylori eradication on bulbitis and duodenal gastric metaplasia.
Hepatogastroenterology 2004; 51:176-180.
18. Suzuki H, Masaoka T, Sakai G, Ishii H, Hibi T. Improvement of
gastrointestinal quality of life scores in cases of Helicobacter
pylori-positive functional dyspepsia after successful eradication
therapy. J Gastroenterol Hepatol 2005; 20: 1652-1660.
19. Türkay C, Soykan I, K›r M, Özden A. The effect of Helicobacter
pylori eradication on symptoms and gastric emptying in patients
with nonulcer dyspepsia. Turk J Gastroenterol 2002;13:146-
153.
20. Valle J, Seppala K, Sipponen P, Kosunen T. Dissapearance of
gastritis after eradication of HP. Amorphometric study. Scand J
Gastroenterol 1991; 26:1057-1065.
21. van der Wouden EJ, Thijs JC, van Zwet AA, Kleibeuker JH. Sixyear
follow-up after successful triple therapy for Helicobacter
pylori infection in patients with peptic ulcer disease. Eur J Gastroenterol
Hepatol 2001; 13: 1235-1239.
22. Zhou LY, Shen ZY, Lin SR, Jin Z, Ding SG, Huang XB, Xia ZW,
Liu JJ, Guo HL, William C. Changes of gastric mucosa histopathology
after Helicobacter pylori eradication Zhonghua Nei Ke
Za Zhi 2003; 42:162-164.

Thank you for copying data from http://www.arastirmax.com